Jesus Hernandez, MD
Physical Medicine & Rehabilitation · New York, NYNPI 1083750913
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 535 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,784 and has fallen 69.0% since, to $863 in 2025. Among physical medicine & rehabilitation clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 535 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Boehringer Ingelheim$1K
- GSK$818
- Novo Nordisk$763
- plus $3K from 24 others
What the payments were for
- Food & beverage$11,87899%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 172 | $2,797 |
| AstraZeneca | 68 | $1,672 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 81 | $1,384 |
| Boehringer Ingelheim | 38 | $1,170 |
| GSK | 21 | $818 |
| Novo Nordisk | 27 | $763 |
| Johnson & Johnson(2 entities) | 14 | $439 |
| Bayer | 15 | $423 |
| Nestle Healthcare Nutrition Inc. | 12 | $315 |
| Lilly USA, LLC | 3 | $255 |
| E.r. Squibb & Sons, L.L.C. | 10 | $245 |
| Pfizer | 11 | $231 |
| Biohaven Pharmaceuticals, Inc. | 6 | $226 |
| Neurocrine Biosciences, Inc. | 1 | $160 |
| Amgen(2 entities) | 8 | $159 |
| Amarin Pharma, Inc. | 9 | $153 |
| Ironwood Pharmaceuticals, Inc | 8 | $133 |
| Idorsia Pharmaceuticals US Inc | 6 | $131 |
| Merck | 7 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $47 |
| Corium, LLC | 3 | $40 |
| Mannkind Corporation | 2 | $40 |
| Novartis | 2 | $32 |
| Ardelyx, Inc. | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Activ Surgical, Inc. | 1 | $26 |
| Bayer Healthcare LLC | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,951 in reported general payments places this provider in the 95th percentile of 872 physical medicine & rehabilitation providers in New York.
See all physical medicine & rehabilitation providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 184 | $170,486 |
| LinzessLinaclotide | 182 | $128,829 |
| EliquisApixaban | 113 | $103,415 |
| FarxigaDapagliflozin Propanediol | 109 | $97,901 |
| TradjentaLinagliptin | 98 | $83,131 |
| VraylarCariprazine Hcl | 22 | $60,542 |
| JanuviaSitagliptin Phosphate | 39 | $47,948 |
| OzempicSemaglutide | 47 | $46,614 |
| KerendiaFinerenone | 57 | $45,259 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $41,531 |
| JanumetSitagliptin Phos/Metformin Hcl | 46 | $33,542 |
| EntrestoSacubitril/Valsartan | 29 | $28,870 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $22,794 |
| Diclofenac Sodium | 367 | $21,603 |
| RybelsusSemaglutide | 19 | $21,441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $1,170 | $253,617282 claims |
| AbbVieLinzess, Vraylar, Creon, Namzaric | $2,797 | $218,723237 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,672 | $120,695147 claims |
| PfizerEliquis | $231 | $103,415113 claims |
| MerckJanuvia, Janumet, Belsomra, Dulera | $124 | $100,561135 claims |
| Novo NordiskOzempic, Rybelsus | $763 | $68,05566 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $818 | $52,474103 claims |
| BayerKerendia | $423 | $45,25957 claims |
| NovartisEntresto | $32 | $28,87029 claims |
| Lilly USA, LLCTrulicity | $255 | $17,36118 claims |
| Aimmune Therapeutics, Inc.Zenpep | $23 | $16,77513 claims |
| Johnson & JohnsonXarelto | $439 | $10,86014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 872 physical medicine & rehabilitation providers in New York.
Other physical medicine & rehabilitation in New York
- Heidi FuscoNew York$153K
- Michael OdellNew York$67K
- Craig AntellNew York$65K
- Michael StubblefieldNew York$53K
- Heakyung KimNew York$53K
- Russell SilverNew York$34K
- Julia IafrateNew York$32K
- Neil JaseyNew York$29K
- Christian CustodioNew York$19K
- Karan JoharNew York$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.